Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: Relating user sensory perceptions and experiences to formulation properties

AIDS Research and Human Retroviruses

Volumn 30, Issue 1, 2014, Pages 78-91

  Morrow, Kathleen M ^a,b   Fava, Joseph L ^a   Rosen, Rochelle K ^a,b   Vargas, Sara ^a,b   Shaw, Julia G ^a   Kojic, E Milu ^a,b   Kiser, Patrick F ^c   Friend, David R ^d   Katz, David F ^e   Barosso, Candelaria ^a   Higgins, Michelle ^a   Wallace, Jacquelyn ^a   Thompson, Lara ^a   Bregman, Dana ^a   Van Den Berg, Jacob ^a   Jensen, Kathleen ^a   Dunsiger, Shira ^a   Panameño, Anacecilia ^a   Colleran, Christopher ^a   Salomon, Liz ^f   Covahey, Charles ^f   Mayer, Kenneth H ^f   Dang, Danielle ^f   Frontiero, Vanessa ^f   Panther, Lori ^f   Peters, Jennifer ^g   Geonnotti, Anthony ^g   Henderson, Marcus ^g   Lai, Bonnie ^g   Clark, Meredith ^c   Tuitupou, Anthony ^c   Fabian, Judith ^c   more..

^a MIRIAM HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c Department of Electrical and Computer Engineering   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f FENWAY INSTITUTE   (United States)

^g DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPOL 974P; DAPIVIRINE; GLYCEROL; HYDROCHLORIC ACID; HYDROXYETHYLCELLULOSE; METHYL PARABEN; MICROBICIDE; PLACEBO; PROPYL PARABEN; PURIFIED WATER; SODIUM CHLORIDE; SODIUM HYDROXIDE; TENOFOVIR; AGENTS USED INTRAVAGINALLY; TOPICAL ANTIINFECTIVE AGENT;

ADULT; ARTICLE; COITUS; CONTROLLED STUDY; DRUG FORMULATION; DRUG TRANSPORT; EVALUATION STUDY; FEMALE; GEL; HUMAN; HUMAN EXPERIMENT; MOBILIZATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORMAL HUMAN; PENETRATIVE SEX; PERCEPTION; PERSONAL EXPERIENCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; USER SENSORY PERCEPTIONS AND EXPERIENCE; VAGINAL GEL; VAGINAL LUBRICATION; VISCOSITY; DRUG DELIVERY SYSTEM; HIV INFECTIONS; INTRAVAGINAL DRUG ADMINISTRATION; MEDICATION COMPLIANCE; MENSTRUAL CYCLE; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA; VAGINA; YOUNG ADULT;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; DRUG DELIVERY SYSTEMS; FEMALE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MENSTRUAL CYCLE; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 84891813026     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0099     Document Type: Article

References (69)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-1174.
2. Padian NS, Buve A, Balkus J, Serwadda D, and Cates WJ: Biomedical interventions to prevent HIV infection: Evidence, challenges, and way forward. Lancet 2008;372(9638):585-599.
3. Rotheram-Borus MJ, Swendeman D, and Chovnick G: The past, present, and future of HIV prevention: Integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol 2009;5:143-167.
4. McGowan I and Dezzutti C: Rectal microbicide development. Curr Top Microbiol Immunol 2013;April 24 [Epub ahead of print].
5. Obiero J, Mwethera PG, Hussey GD, and Wiysonge CS: Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: Systematic review and meta-analysis. BMC Infect Dis 2012;12(289):1471-2334.
6. McGowan I: Microbicides for HIV prevention: Reality or hope? Curr Opinion Infect Dis 2010;26:26-31.
7. Obiero J, Mwethera PG, and Wiysonge CS: Topical microbicides for prevention of sexually transmitted infections. Cochrane Database Syst Rev 2012;13(6): CD007961.
8. Verguet S and Walsh JA: Vaginal microbicides save money: A model of cost-effectiveness in South Africa and the USA. Sex Transm Infect 2010;86(3):212-216.
9. Vickerman P, Watts C, Delany S, Alary M, Rees H, and Heise L: The importance of context: Model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis 2006;33(6):397-405.
10. Watts C and Vickerman P: The impact of microbicides on HIV and STD transmission: Model projections. AIDS 2001; 15:S43-S44.
11. Terris-Prestholt F: Model projections of the population-level impact, on HIV and herpes simplex virus type-2 (HSV-2) and cost-effectiveness of tenofovir gel, an antiretroviral microbicide. Paper presented at the XIX International AIDS Conference, July 22-27, 2012, Washington, DC.
12. de Bruin M and Viechtbauer W: The meaning of adherence when behavioral risk patterns vary: Obscured use-and method-effectiveness in HIV-prevention trials. PLoS One 2012;7(8):31.
13. Morrow K, Rosen R, Vargas S, Barroso C, Kiser P, and Katz D: User-identified vaginal gel characteristics: A qualitative exploration of perceived product efficacy. Paper presented at the International Microbicides 2010 Conference, May 24, 2010, Pittsburgh, PA.
14. Morrow KM and Ruiz MS: Assessing microbicide acceptability: A comprehensive and integrated approach. AIDS Behav 2008;12(2):272-283.
15. Thurman AR, Clark MR, and Doncel GF: Multipurpose prevention technologies: Biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol 2011;2011:1-10.
16. Tolley EE, Harrison PF, Goetghebeur E, et al.: Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav 2010;14(5):1124-1136.
17. Baeten JM, Donnell D, Ndase P, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367(5):399-410.
18. Cohen MS, Chen YQ, McCauley M, et al.: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505.
19. Grant RM, Lama JR, Anderson PL, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
20. Landovitz RJ and Currier JS: Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med 2009;361(18): 1768-1775.
21. Abdool Karim SS, Richardson BA, Ramjee G, et al.: Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011;25(7):957-966.
22. Carraguard Phase II South Africa Study Team: Expanded safety and acceptability of the candidate vaginal microbicide carraguard in South Africa. Contraception 2010;82(6):563-571.
23. Greene E, Batona G, Hallad J, Johnson S, Neema S, and Tolley EE: Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India. Cult Health Sex 2010;12(7):739-754.
24. Kamali A, Byomire H, Muwonge C, et al.: A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal and microbicide gel in sexually active women in Uganda. Sex Transm Infect 2010;86(3):222-226.
25. Kilmarx PH, van de Wijgert JH, Chaikummao S, et al.: Safety and acceptability of the candidate microbicide Carraguard in Thai Women: Findings from a Phase II clinical trial. J Acquir Immune Defic Syndr 2006;43(3):327-334.
26. McCormack S, Ramjee G, Kamali A, et al.: PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, doubleblind, parallel-group trial. Lancet 2010;376(9749):1329- 1337.
27. Microbicide Trials Network: Daily HIV prevention approaches didn't work for African Women in the VOICE Study. 2013; www.mtnstopshiv.org/node/4877
28. McGowan I, Gomez K, Bruder K, et al.: Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 2011;25(8):1057-1064.
29. Adams JL and Kashuba ADM: Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol 2012;26(4):451-462.
30. Marrazzo J, Ramjee G, Nair G, et al.: Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/ emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Paper presented at The Conference on Retroviruses and Opportunistic Infections (CROI), 2012.
31. Shihata AA and Brody SA: HIV prevention by enhancing compliance of tenofovir microbicide. Using a novel delivery system. HIV AIDS Rev 2010;9(4):105-108.
32. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, and Frick PA: Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 2006; 10(3):227-245.
33. Hootman RC: Manual on Descriptive Analysis Testing for Sensory Evaluation. ASTM International, West Conshohocken, Pennsylvania, 1992.
34. Meilgaard M, Civille GV, and Carr BT: Sensory Evaluation Techniques, 3rd ed. CRC Press LLC, Boca Raton, FL, 1999.
35. Ziegler G, Mongia G, and Hollender R: The role of particle size distribution of suspended solids in defining the sensory properties of milk chocolate. Int J Food Prop 2001;4(2):353-370.
36. Marty JP, Lafforgue C, Grossiord JL, and Soto P: Rheological properties of three different vitamin D ointments and their clinical perception by patients with mild to moderate psoriasis. J Eur Acad Dermatol Venereol 2005;19(s3):7-10.
37. DeMartine ML and Cussler EL: Predicting subjective spreadability, viscosity, and stickiness. J Pharm Sci 1975;64(6):976-982.
38. Mahan ED, Morrow KM, and Hayes JE: Quantitative perceptual differences among over-the-counter vaginal products using a standardized methodology: Implications for microbicide development. Contraception 2011;84(2):184-193.
39. Tien D, Schnaare RL, Kang F, et al.: In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 2005;21(10):845-853.
40. Katz DF, Gao Y, and Kang M: Using modeling to help understand vaginal microbicide functionality and create better products. Drug Deliv Transl Res 2011;1(3):256-276.
41. Centers for Disease Control and Prevention (CDC): HIV among Women, 2011.
42. Bunge K, Macio I, Meyn L, et al.: The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781. J Acquir Immune Defic Syndr 2012;60(4):337-343.
43. ClinicalTrials.gov. An Expanded Safety Study of Dapivirine Gel 4789 in Africa, 2013; http://clinicaltrials.gov/show/ NCT00917904
44. FACTS Consortium. FACTS 001 Study, 2011; http://facts consortium.wordpress.com/facts-001-study/
45. Haaland RE, Evans-Strickfaden T, Holder A, et al.: UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application. Antimicrob Agents Chemother 2012;56(7):3592-3596.
46. Mascolini M: HIV Prevention Fails in All Three VOICE Arms, as Daily Truvada PrEP Falls. Paper presented at the 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA.
47. Microbicide Trials Network. Fact Sheet Results - Understanding the Results of VOICE. 2013; www.mtnstop shiv.org/node/2003
48. Skoler-Karpoff S, Ramjee G, Ahmed K, et al.: Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9654):1977-1987.
49. El-Sadr W, Mayer K, Maslankowski L, et al.: Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS 2006;20(8):1109-1116.
50. Kiser PF, Mahalingam A, Fabian J, et al.: Design of Tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci 2012;101(5):1852-1864.
51. Mahalingam A, Smith E, Fabian J, et al.: Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res 2010;27(11):2478-2491.
52. Nel AM, Smythe SC, Habibi S, Kaptur PE, and Romano JW: Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010;55(2):161-169.
53. Owen DH and Katz DF: A vaginal fluid simulant. Contraception 1999;59(2):91-95.
54. Lai BE, Xie YQ, Lavine ML, Szeri AJ, Owen DH, and Katz DF: Dilution of microbicide gels with vaginal fluid and se-men simulants: Effect on rheological properties and coating flow. J Pharm Sci 2008;97(2):1030-1038.
55. Tasoglu S, Katz DF, and Szeri AJ: Transient spreading and swelling behavior of a gel deploying an anti-HIV topical microbicide. J Nonnewton Fluid Mech 2012;188: 36-42.
56. Tasoglu S, Peters JJ, Park SC, Verguet S, Katz DF, and Szeri AJ: The effects of inhomogeneous boundary dilution on the coating flow of an anti-HIV microbicide vehicle. Phys Fluids 2011;23(9):93101-931019.
57. Mahalingam A, Simmons AP, Ugaonkar SR, et al.: Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother 2011;55(4):1650-1660.
58. Ham AS, Ugaonkar SR, Shi L, et al.: Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci 2012;101(4):1423-1435.
59. Jogelkar N, Joshi S, Kakde M, et al.: Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care 2007;19(6):817-821.
60. Ramjee G, Morar NS, Braunstein S, Friedland B, Jones H, and van de Wijgert J: Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS Res Ther 2007;4:20.
61. Bentley ME, Fullem AM, Tolley EE, et al.: Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Pub Health 2004;94(7):1159-1164.
62. Rosen RK, Morrow KM, Carballo-Dieguez A, et al.: Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: A mixed-methods study. J Womens Health (Larchmt) 2008;17(3):383-392.
63. Fava JL, van den Berg JJ, Rosen RK, et al.: Measuring selfefficacy to use vaginal microbicides: The microbicide use self-efficacy instrument. Sex Health 2013;28(10):339-347.
64. Morrow K, Fava J, Kiser P, Rosen R, and Katz D: The LINK between gel properties and user perceptions: Implications for rational design of microbicides. Paper presented at the International Microbicides 2010 Conference, May 23, 2010, Pittsburgh, PA.
65. Morrow KM, Fava JL, Rosen RK, Christensen AL, Vargas S, and Barroso C: Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type. Health Psychol 2007;26(6):777-786.
66. Morrow KM, Fava JL, Rosen RK, et al.: Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties. J Acquir Immune Defic Syndr 2007;45(1):93-101.
67. Comrey AL and Lee HB: A First Course in Factor Analysis, 2nd ed. Lawrence Erlbaum, Hillsdale, NJ, 1992.
68. Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
69. Cohen J: Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Lawrence Erlbaum, Hillsdale, NJ, 1988.